Skylands Capital LLC Grows Holdings in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Skylands Capital LLC increased its holdings in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 87.5% in the fourth quarter, Holdings Channel reports. The firm owned 6,986 shares of the medical equipment provider’s stock after acquiring an additional 3,261 shares during the period. Skylands Capital LLC’s holdings in Zimmer Biomet were worth $738,000 as of its most recent SEC filing.

Other institutional investors have also made changes to their positions in the company. Stonebridge Financial Group LLC acquired a new stake in shares of Zimmer Biomet in the 4th quarter valued at about $25,000. Dunhill Financial LLC increased its holdings in shares of Zimmer Biomet by 1,090.0% during the third quarter. Dunhill Financial LLC now owns 238 shares of the medical equipment provider’s stock valued at $26,000 after purchasing an additional 218 shares during the period. Ashton Thomas Securities LLC bought a new stake in shares of Zimmer Biomet in the 3rd quarter worth $28,000. Brooklyn Investment Group acquired a new stake in Zimmer Biomet during the third quarter valued at approximately $35,000. Finally, Kentucky Trust Co acquired a new position in shares of Zimmer Biomet in the 4th quarter valued at $39,000. 88.89% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of research analysts recently commented on the stock. JMP Securities reaffirmed a “market outperform” rating and set a $140.00 price objective on shares of Zimmer Biomet in a research report on Friday, February 7th. Raymond James dropped their target price on shares of Zimmer Biomet from $126.00 to $119.00 and set an “outperform” rating on the stock in a report on Friday, February 7th. Truist Financial reiterated a “hold” rating and set a $113.00 price target (down from $118.00) on shares of Zimmer Biomet in a report on Monday, February 10th. Royal Bank of Canada dropped their target price on shares of Zimmer Biomet from $130.00 to $125.00 and set an “outperform” rating on the stock in a research report on Friday, February 7th. Finally, Wells Fargo & Company increased their price target on shares of Zimmer Biomet from $110.00 to $117.00 and gave the company an “equal weight” rating in a report on Thursday, October 31st. Two research analysts have rated the stock with a sell rating, eleven have issued a hold rating and nine have issued a buy rating to the stock. According to data from MarketBeat.com, Zimmer Biomet has a consensus rating of “Hold” and a consensus target price of $124.15.

Zimmer Biomet Stock Performance

NYSE ZBH opened at $104.89 on Monday. The firm has a market cap of $20.88 billion, a price-to-earnings ratio of 23.57, a PEG ratio of 1.95 and a beta of 1.02. The company has a current ratio of 1.91, a quick ratio of 0.99 and a debt-to-equity ratio of 0.43. Zimmer Biomet Holdings, Inc. has a 1-year low of $97.69 and a 1-year high of $133.90. The company has a 50 day moving average of $105.86 and a 200-day moving average of $107.46.

Zimmer Biomet (NYSE:ZBH) last issued its quarterly earnings data on Thursday, February 6th. The medical equipment provider reported $2.31 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.30 by $0.01. Zimmer Biomet had a return on equity of 12.99% and a net margin of 11.77%. During the same period in the prior year, the business posted $2.20 earnings per share. On average, equities analysts forecast that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current fiscal year.

Zimmer Biomet Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Friday, January 31st. Shareholders of record on Monday, December 30th were given a $0.24 dividend. This represents a $0.96 annualized dividend and a yield of 0.92%. The ex-dividend date of this dividend was Monday, December 30th. Zimmer Biomet’s payout ratio is presently 21.57%.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.